Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW))) announced that the Company received notice from The Nasdaq Stock Market ("Nasdaq") on April 23, 2024, notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Rule 5550(a)(2).
Mark White, CEO of Nexalin, stated, "We remain committed to our mission of revolutionizing the treatment of mental health and neurological conditions through our safe, non-invasive, and drug-free neurostimulation technology. We believe our Nasdaq listing provides us with much greater exposure within the investment community, which is particularly important given the positive ongoing developments and anticipated upcoming milestones. I would like to extend my gratitude to our shareholders for your continued support and confidence in Nexalin's vision and capabilities."